CN102014627B - 作为极光激酶抑制剂的稠合双环嘧啶化合物 - Google Patents

作为极光激酶抑制剂的稠合双环嘧啶化合物 Download PDF

Info

Publication number
CN102014627B
CN102014627B CN200980115577.4A CN200980115577A CN102014627B CN 102014627 B CN102014627 B CN 102014627B CN 200980115577 A CN200980115577 A CN 200980115577A CN 102014627 B CN102014627 B CN 102014627B
Authority
CN
China
Prior art keywords
compound
esi
nmr
cdcl
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980115577.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102014627A (zh
Inventor
谢兴邦
M·S·考玛
徐祖安
伍素萤
赵宇生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Health Research Institutes
Original Assignee
National Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Health Research Institutes filed Critical National Health Research Institutes
Publication of CN102014627A publication Critical patent/CN102014627A/zh
Application granted granted Critical
Publication of CN102014627B publication Critical patent/CN102014627B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN200980115577.4A 2008-04-30 2009-04-22 作为极光激酶抑制剂的稠合双环嘧啶化合物 Expired - Fee Related CN102014627B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4906308P 2008-04-30 2008-04-30
US61/049,063 2008-04-30
PCT/US2009/041382 WO2009134658A2 (en) 2008-04-30 2009-04-22 Fused bicyclic pyrimidine compounds as aurora kinase inhibitors

Publications (2)

Publication Number Publication Date
CN102014627A CN102014627A (zh) 2011-04-13
CN102014627B true CN102014627B (zh) 2014-10-29

Family

ID=41255689

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980115577.4A Expired - Fee Related CN102014627B (zh) 2008-04-30 2009-04-22 作为极光激酶抑制剂的稠合双环嘧啶化合物

Country Status (12)

Country Link
US (1) US8138194B2 (enExample)
EP (1) EP2276346B1 (enExample)
JP (1) JP5502072B2 (enExample)
KR (1) KR101667822B1 (enExample)
CN (1) CN102014627B (enExample)
AU (1) AU2009241469B2 (enExample)
CA (1) CA2722220C (enExample)
DK (1) DK2276346T3 (enExample)
ES (1) ES2616255T3 (enExample)
PL (1) PL2276346T3 (enExample)
TW (1) TWI363627B (enExample)
WO (1) WO2009134658A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012130929A (ru) * 2009-12-23 2014-01-27 Байокрист Фармасьютикалз, Инк. Гетероциклические соединения в качестве ингибиторов янус-киназы
KR20120124428A (ko) 2009-12-30 2012-11-13 아르퀼 인코포레이티드 치환된 피롤로-아미노피리미딘 화합물
WO2012061342A2 (en) 2010-11-01 2012-05-10 Arqule, Inc. Substituted benzo-imidazo-pyrido-diazepine compounds
CN104321322A (zh) * 2012-03-30 2015-01-28 理森制药股份公司 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
CN104470931B (zh) 2012-05-21 2016-10-26 拜耳医药股份有限公司 取代的苯并噻吩并嘧啶
CA2873971A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyrimidines
CN104507950B (zh) 2012-05-21 2017-03-22 拜耳医药股份有限公司 噻吩并嘧啶
EA025186B1 (ru) 2012-06-29 2016-11-30 Пфайзер Инк. НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
CN103664993B (zh) * 2012-09-25 2016-05-25 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
CN105189518A (zh) 2013-02-01 2015-12-23 拜耳制药股份公司 取代的噻吩并吡啶和其药物用途
HK1220972A1 (zh) 2013-03-06 2017-05-19 Bayer Pharma Aktiengesellschaft 取代的噻唑并嘧啶
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
SG11201607990QA (en) 2014-04-25 2016-11-29 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN105061461B (zh) * 2015-08-18 2017-06-30 沈阳药科大学 含有苄胺结构的四氢苯并[4,5]噻吩并[2,3‑d]嘧啶类化合物及其应用
CN105061460B (zh) * 2015-08-18 2017-06-30 沈阳药科大学 含有硫醚结构的四氢苯并[4,5]噻吩并[2,3‑d]嘧啶类化合物及其应用
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN106243124B (zh) * 2016-07-29 2018-03-09 湖北民族学院 一种噻吩并嘧啶脲类化合物及其制备方法和应用
AU2017315343A1 (en) 2016-08-24 2019-02-28 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
CN106810512B (zh) * 2017-01-18 2019-09-10 江苏省中医药研究院 Idh2突变体抑制剂及其用途
CR20200124A (es) * 2017-08-15 2020-09-28 Abbvie Inc Inhibidores macrocíclicos de mcl-1 y métodos de uso
MX2020001719A (es) * 2017-08-15 2020-11-06 Abbvie Inc Inhibidores macrocíclicos de mcl-1 y metodos de uso.
AU2018317828A1 (en) * 2017-08-15 2020-04-02 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
US12492204B2 (en) 2019-08-26 2025-12-09 Chemwerth, Inc. Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl) amino compounds useful as JAK 1 inhibitors
CN112500421B (zh) * 2020-12-15 2021-08-24 河南科技大学第一附属医院 一种可用于杀菌消毒的苯并吡喃脲类化合物的制备方法及应用
TW202413367A (zh) * 2022-08-19 2024-04-01 財團法人國家衛生研究院 Ｔａｍ受體抑制劑
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032872A1 (fr) * 2000-10-20 2002-04-25 Eisai Co., Ltd. Composes a noyau aromatique azote
US20050277658A1 (en) * 2003-10-14 2005-12-15 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein kinase inhibitors
US20070027166A1 (en) * 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
WO2007053343A2 (en) * 2005-10-28 2007-05-10 Irm Llc Compounds and compositions as protein kinase inhibitors
CN101160316A (zh) * 2004-07-16 2008-04-09 苏内西斯医药公司 适合用作aurora激酶抑制剂的噻吩并嘧啶

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008726A1 (de) * 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
DE10141212A1 (de) 2001-08-22 2003-03-06 Bayer Ag Neue 4-Aminofuropyrimidine und ihre Verwendung
AU2002333524A1 (en) 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
US6814324B2 (en) * 2002-07-03 2004-11-09 Segway Systems, Llc Releasably latchable leader block in tape threading apparatus for data storage systems and method therefor
UA83814C2 (ru) 2002-12-24 2008-08-26 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение
US20050153989A1 (en) 2004-01-13 2005-07-14 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
KR101792651B1 (ko) 2004-05-14 2017-11-20 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물
JP2008505084A (ja) 2004-06-29 2008-02-21 アムゲン インコーポレイティッド フラノピリミジン
JP2008505167A (ja) 2004-07-05 2008-02-21 アステックス、セラピューティックス、リミテッド 医薬組成物
DE602005024274D1 (de) * 2004-07-16 2010-12-02 Sunesis Pharmaceuticals Inc Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
WO2007076348A2 (en) 2005-12-23 2007-07-05 Smithkline Beecham Corporation Azaindole inhibitors of aurora kinases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032872A1 (fr) * 2000-10-20 2002-04-25 Eisai Co., Ltd. Composes a noyau aromatique azote
US20050277658A1 (en) * 2003-10-14 2005-12-15 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein kinase inhibitors
CN101160316A (zh) * 2004-07-16 2008-04-09 苏内西斯医药公司 适合用作aurora激酶抑制剂的噻吩并嘧啶
US20070027166A1 (en) * 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
WO2007053343A2 (en) * 2005-10-28 2007-05-10 Irm Llc Compounds and compositions as protein kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
New 4-Amino-7,8-dimethoxy-5H-pyrimido[5,4-b]indole Derivatives:Synthesis and Studies as Inhibitors of Phosphodiesterases;Antonio Monge et al.;《Archiv der Pharmazie 》;19931231;第326卷(第11期);第879-885页 *

Also Published As

Publication number Publication date
CA2722220A1 (en) 2009-11-05
WO2009134658A3 (en) 2009-12-30
EP2276346A2 (en) 2011-01-26
EP2276346B1 (en) 2016-11-23
PL2276346T3 (pl) 2017-07-31
KR20100132067A (ko) 2010-12-16
KR101667822B1 (ko) 2016-10-19
HK1151694A1 (en) 2012-02-10
AU2009241469B2 (en) 2015-05-07
US20090275533A1 (en) 2009-11-05
CA2722220C (en) 2016-06-07
TW200948365A (en) 2009-12-01
JP5502072B2 (ja) 2014-05-28
TWI363627B (en) 2012-05-11
DK2276346T3 (en) 2017-02-27
EP2276346A4 (en) 2011-08-24
CN102014627A (zh) 2011-04-13
JP2011522789A (ja) 2011-08-04
US8138194B2 (en) 2012-03-20
ES2616255T3 (es) 2017-06-12
AU2009241469A1 (en) 2009-11-05
WO2009134658A2 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
CN102014627A (zh) 作为极光激酶抑制剂的稠合双环嘧啶化合物
JP5781934B2 (ja) チロシンキナーゼ阻害剤としての融合２環および３環ピリミジン化合物
EP2331530B1 (en) Fused multicyclic compounds as protein kinase inhibitors
KR100597505B1 (ko) 4-아미노-6-페닐-피롤로[2,3-ｄ]피리미딘 유도체
KR102677015B1 (ko) Bet 억제제로서의 헤테로시클릭 화합물
WO2012098068A1 (en) Pyrazolo pyrimidines as dyrk1a and dyrk1b inhibitors
CA2864672C (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
HK1151694B (en) Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
HK1162509B (en) Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
HK1163089B (en) Fused multicyclic compounds as protein kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1151694

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1151694

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141029

CF01 Termination of patent right due to non-payment of annual fee